Let us cooperate on precise health technologies
International cooperation is key to fulfilling our vision of making cancer treatments more precise, and giving the patients new treatments more quickly.
Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
SmiLe Incubator and several of the incubator companies are attending BIO-Europe November 5-7 in Copenhagen. This year the life sciences partnering conference, the largest in Europe, is being held outside the German speaking countries for the first time. It is also record-breaking in size: 4,400 attendees and 122,000 prearranged meetings.
SmiLe company Nordic Rebalance is launching its product Refermin on November 5. Refermin is a fermented oat drink that contains beneficial fermentation products and health-promoting bacteria. The drink has been shown to have a clinical effect and relieves symptoms of IBS and ulcerative colitis. Refermin is sold online at www.refermin.se.
InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2019 Annual General Meeting, which will be held on Monday May 6, 2019. The responsibility of the Nomination Committee is to present to the 2019 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a standard of care chemoimmunotherapy regimen
Redoxis will be represented at BioEurope taking place in Copenhagen 5-7th of November.
Saxenda® is the first and only FDA-approved medicine in a pen indicated to help adults lose weight and keep it off
The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors.
Swedish Medical Products Agency and Ethics Committee have announced that they approve Gedea’s first clinical study. The study is an important step prior to CE marking ofpHyph, which is a completely new type of treatment for vaginal infection. pHyph is expected to be able to treat both vaginal fungal infections and bacterial vaginosis and may become the first product on the market for treatment of both types of infection.
In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical remission (per Full Mayo Score) and clinical response, in patients with moderately to severely active ulcerative colitis
InDex Pharmaceuticals Holding AB (publ) today announced the publication of a post-hoc analysis of COLLECT study data. COLLECT was a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod, a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC).